[Antifibrinolytic agents and their therapeutic use].
D000614:Aminocaproates / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D007611:Aprotinin; D001565:Benzoates / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology; D001779:Blood Coagulation Factors; D001787:Blood Group Incompatibility / Q000150:complications; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005112:Extracorporeal Circulation / Q000009:adverse effects; D005260:Female; D006801:Humans; D007705:Kinins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic; D011480:Protease Inhibitors; D012790:Shwartzman Phenomenon / Q000150:complications; D013916:Thrombelastography; D014688:Venoms / Q000009:adverse effects
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D001565:Benzoates; D001779:Blood Coagulation Factors; D003509:Cyclohexanecarboxylic Acids; D007705:Kinins; D011480:Protease Inhibitors; D014688:Venoms; D007611:Aprotinin
Antifibrinolytika und deren therapeutische Anwendung.